NCT02498613 [39] is an open-label phase II trial studying cediranib maleate (vascular endothelial growth factor (VEGF)-tyrosine kinase inhibitor (TKI)) combined with olaparib in advanced breast, non-small-cell and small-cell lung cancer, and pancreatic cancer patients. Here, VEGFA is linked to non-small cell lung carcinoma.